The production of three kinds of peptizine granules will be approved soon

Prior to that, Deng Xiang, Secretary of the board of directors of Hisilicon, predicted that the product is expected to be approved in 2014, and the sales revenue after IPO will reach 300 million yuan Polyprizine granules are digestive drugs, the main component is polyprizine, used in the treatment of gastric ulcer This product is the only new type of gastric mucosa protective agent with multi-layer repair mechanism and long-term physical coverage, which can effectively reduce the recurrence rate of ulcer It is significantly superior to the traditional gastric mucosa protective agent in terms of safety, and is listed as one of the "top ten prescription drugs in China in 2012" According to the data, polyprizin is a new generation of anti gastric ulcer drug developed by hamari new drug industry Co., Ltd in Japan It is the first zinc containing compound for clinical use and passed the review of Japan's Ministry of health and health in 1994 In China, at present, only Jilin Boda Weiye Pharmaceutical Co., Ltd is a manufacturer of jupurui zinc granules Hisic is mainly engaged in the production and sales of chemical pharmaceutical preparations and APIs The company focuses on R & D and new product investment According to the data of 2014 China Daily, from January to June 2014, the R & D investment of the company reached 88.59 million yuan, up 75% from 50.44 million yuan in the same period of 2013 In the same period, due to the promotion of new products, the sales expenses reached 82.36 million yuan, an increase of 39% year on year.